AGM/EGMJun 18, 2026, 04:37 PM
Protagonist Therapeutics Stockholders Approve 2026 Equity Plan
AI Summary
Protagonist Therapeutics held its 2026 Annual Meeting of Stockholders, where all four proposals were approved. Key approvals included the adoption of the 2026 Equity Incentive Plan, which authorizes 650,000 new shares and incorporates shares returned from the previous plan. Stockholders also re-elected two Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
Key Highlights
- Stockholders approved the 2026 Equity Incentive Plan, replacing the 2016 Plan.
- The 2026 Plan authorizes 650,000 new shares plus shares returned from the 2016 Plan.
- Dinesh V. Patel, Ph.D. was elected as a Class I director with 48,714,702 votes.
- Lewis T. "Rusty" Williams, M.D., Ph.D. was elected as a Class I director with 45,371,193 votes.
- Advisory approval of named executive officer compensation received 53,412,559 votes.
- Ernst & Young LLP was ratified as the independent auditor for 2026 with 59,371,487 votes.
Price Impact
More from PTGX